These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 33871687)

  • 1. Stimulant treatment effectiveness, safety and risk for psychosis in individuals with 22q11.2 deletion syndrome.
    Basel D; Mosheva M; Maeder J; Schneider M; Shani S; Weinberger R; Eliez S; Gothelf D
    Eur Child Adolesc Psychiatry; 2022 Sep; 31(9):1367-1375. PubMed ID: 33871687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biological effects of COMT haplotypes and psychosis risk in 22q11.2 deletion syndrome.
    Gothelf D; Law AJ; Frisch A; Chen J; Zarchi O; Michaelovsky E; Ren-Patterson R; Lipska BK; Carmel M; Kolachana B; Weizman A; Weinberger DR
    Biol Psychiatry; 2014 Mar; 75(5):406-13. PubMed ID: 23992923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Attention deficit hyperactivity disorder symptoms as antecedents of later psychotic outcomes in 22q11.2 deletion syndrome.
    Niarchou M; Chawner SJRA; Fiksinski A; Vorstman JAS; Maeder J; Schneider M; Eliez S; Armando M; Pontillo M; Vicari S; McDonald-McGinn DM; Emanuel BS; Zackai EH; Bearden CE; Shashi V; Hooper SR; Owen MJ; Gur RE; Wray NR; van den Bree MBM; Thapar A;
    Schizophr Res; 2019 Feb; 204():320-325. PubMed ID: 30093352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Further evidence for high rates of schizophrenia in 22q11.2 deletion syndrome.
    Monks S; Niarchou M; Davies AR; Walters JT; Williams N; Owen MJ; van den Bree MB; Murphy KC
    Schizophr Res; 2014 Mar; 153(1-3):231-6. PubMed ID: 24534796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Attention Deficit Hyperactivity Disorder Symptoms and Psychosis in 22q11.2 Deletion Syndrome.
    Niarchou M; Calkins ME; Moore TM; Tang SX; McDonald-McGinn DM; Zackai EH; Emanuel BS; Gur RC; Gur RE
    Schizophr Bull; 2018 Jun; 44(4):824-833. PubMed ID: 29040797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and side effects of psychopharmacotherapy in individuals with 22q11.2 deletion syndrome with comorbid psychiatric disorders: a systematic review.
    Mosheva M; Korotkin L; Gur RE; Weizman A; Gothelf D
    Eur Child Adolesc Psychiatry; 2020 Aug; 29(8):1035-1048. PubMed ID: 30949827
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The feasibility and safety of S-adenosyl-L-methionine (SAMe) for the treatment of neuropsychiatric symptoms in 22q11.2 deletion syndrome: a double-blind placebo-controlled trial.
    Green T; Steingart L; Frisch A; Zarchi O; Weizman A; Gothelf D
    J Neural Transm (Vienna); 2012 Nov; 119(11):1417-23. PubMed ID: 22678699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of COMT and PRODH gene variants with intelligence quotient (IQ) and executive functions in 22q11.2DS subjects.
    Carmel M; Zarchi O; Michaelovsky E; Frisch A; Patya M; Green T; Gothelf D; Weizman A
    J Psychiatr Res; 2014 Sep; 56():28-35. PubMed ID: 24853458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between a common haplotype in the COMT gene region and psychiatric disorders in individuals with 22q11.2DS.
    Michaelovsky E; Gothelf D; Korostishevsky M; Frisch A; Burg M; Carmel M; Steinberg T; Inbar D; Apter A; Weizman A
    Int J Neuropsychopharmacol; 2008 May; 11(3):351-63. PubMed ID: 17949513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Negative subthreshold psychotic symptoms distinguish 22q11.2 deletion syndrome from other neurodevelopmental disorders: A two-site study.
    Mekori-Domachevsky E; Guri Y; Yi J; Weisman O; Calkins ME; Tang SX; Gross R; McDonald-McGinn DM; Emanuel BS; Zackai EH; Zalsman G; Weizman A; Gur RC; Gur RE; Gothelf D
    Schizophr Res; 2017 Oct; 188():42-49. PubMed ID: 28041919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Robust and replicable functional brain signatures of 22q11.2 deletion syndrome and associated psychosis: a deep neural network-based multi-cohort study.
    Supekar K; de Los Angeles C; Ryali S; Kushan L; Schleifer C; Repetto G; Crossley NA; Simon T; Bearden CE; Menon V
    Mol Psychiatry; 2024 Oct; 29(10):2951-2966. PubMed ID: 38605171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The clinical presentation of attention deficit-hyperactivity disorder (ADHD) in children with 22q11.2 deletion syndrome.
    Niarchou M; Martin J; Thapar A; Owen MJ; van den Bree MB
    Am J Med Genet B Neuropsychiatr Genet; 2015 Dec; 168(8):730-8. PubMed ID: 26400629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effectiveness and tolerability of pharmacotherapy for psychosis in 22q11.2 Deletion Syndrome: A systematic review.
    Tanham M; Chen R; Warren N; Heussler H; Scott JG
    Aust N Z J Psychiatry; 2024 May; 58(5):393-403. PubMed ID: 38383990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The clinical course of individuals with 22q11.2 deletion syndrome converting to psychotic disorders: a long-term retrospective follow-up.
    Kulikova K; Schneider M; McDonald McGinn DM; Dar S; Taler M; Schwartz-Lifshitz M; Eliez S; Gur RE; Gothelf D
    Eur Child Adolesc Psychiatry; 2024 Dec; 33(12):4371-4379. PubMed ID: 38834873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deep psychophysiological phenotyping of adolescents and adults with 22q11.2 deletion syndrome: a multilevel approach to defining core disease processes.
    Parker DA; Cubells JF; Imes SL; Ruban GA; Henshey BT; Massa NM; Walker EF; Duncan EJ; Ousley OY
    BMC Psychiatry; 2023 Jun; 23(1):425. PubMed ID: 37312091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neutrophils to lymphocytes ratio and psychosis in 22q11.2 deletion syndrome - Clinical and scientific implications.
    Mekori-Domachevsky E; Taler M; Weinberger R; Guri Y; Dar S; Shani S; Dekel I; Weizman A; Gothelf D
    Schizophr Res; 2021 May; 231():164-169. PubMed ID: 33866261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevated Proinflammatory Markers in 22q11.2 Deletion Syndrome Are Associated With Psychosis and Cognitive Deficits.
    Mekori-Domachevsky E; Taler M; Shoenfeld Y; Gurevich M; Sonis P; Weisman O; Weizman A; Gothelf D
    J Clin Psychiatry; 2017; 78(9):e1219-e1225. PubMed ID: 29141125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Education and employment trajectories from childhood to adulthood in individuals with 22q11.2 deletion syndrome.
    Mosheva M; Pouillard V; Fishman Y; Dubourg L; Sofrin-Frumer D; Serur Y; Weizman A; Eliez S; Gothelf D; Schneider M
    Eur Child Adolesc Psychiatry; 2019 Jan; 28(1):31-42. PubMed ID: 29934817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Effectiveness and Safety of Antipsychotic and Antidepressant Medications in Individuals with 22q11.2 Deletion Syndrome.
    Dori N; Green T; Weizman A; Gothelf D
    J Child Adolesc Psychopharmacol; 2017 Feb; 27(1):83-90. PubMed ID: 26131914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Developmental changes in multivariate neuroanatomical patterns that predict risk for psychosis in 22q11.2 deletion syndrome.
    Gothelf D; Hoeft F; Ueno T; Sugiura L; Lee AD; Thompson P; Reiss AL
    J Psychiatr Res; 2011 Mar; 45(3):322-31. PubMed ID: 20817203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.